TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23103430

Group type: EXPERIMENTAL
Intervention: Group singing training 3 times weekly for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Group music appreciation and relaxation for 12 weeks
Number of subjects: 24
Study: 20653378

Group type: EXPERIMENTAL
Intervention: Virtual Patients (VP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Regular exams
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Web-SP (delayed assessments)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Regular exams (delayed assessments)
Number of subjects: 49
Study: 18416072

Group type: EXPERIMENTAL
Intervention: Combined use of acupuncture and Chinese medicines
Number of subjects: 93

Group type: COMPARATOR
Intervention: Western medicines
Number of subjects: 93
Study: 17021267

Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral supplementation (PO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 8
Study: 14656060

Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibratory proprioceptive stimulation
Number of subjects: 0
Study: 10817313

Group type: EXPERIMENTAL
Intervention: Post-discharge programme
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard aftercare (Control)
Number of subjects: 204
Study: 8872691

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (10 micrograms) followed by 12 ml of saline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural bupivacaine (12 ml of 0.25% bupivacaine)
Number of subjects: 40
Study: 1642922

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide in oxygen with fentanyl
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxygen and air (FIO2 = 0.5) with fentanyl
Number of subjects: 20
Study: 6288627

Group type: EXPERIMENTAL
Intervention: Guar (5 or 10 g) in aqueous solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guar (mixed with a test meal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wheat bran (any dosage)
Number of subjects: 0
Study: 30798104

Group type: EXPERIMENTAL
Intervention: Meditation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control groups
Number of subjects: 0
Study: 30259703

Group type: EXPERIMENTAL
Intervention: AX (astaxanthin 12 mg, tocotrienol 10 mg, zinc 6 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 26843086

Group type: EXPERIMENTAL
Intervention: MEDI4212 (subcutaneous doses of 5, 15, 60, 150, or 300 mg; intravenous dose of 300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omalizumab (subcutaneous)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24796769

Group type: EXPERIMENTAL
Intervention: Radioimmunoassay (RIA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Homogeneous mobility shift assay (HMSA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Functional cell-based reporter gene assay (RGA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: All assays
Number of subjects: 66
Study: 21593352

Group type: EXPERIMENTAL
Intervention: 30 g l-glutamine (Gln-30)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 15 g L-glutamine (Gln-15)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 mg SIT
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 mg SIT and 15 g L-glutamine (SIT+Gln-15)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 15
Study: 19920419

Group type: EXPERIMENTAL
Intervention: T2 and T3 thoracic RF thermolesion
Number of subjects: 50

Group type: COMPARATOR
Intervention: T2 thermolesion with local application of 0.5 mL of 6% phenol
Number of subjects: 50
Study: 16834836

Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg for 8 weeks
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg for 12 weeks (controlled patients)
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg/day
Number of subjects: 823

Group type: COMPARATOR
Intervention: Olmesartan 40 mg/day or olmesartan 20 mg/day plus 12.5 mg hydrochlorothiazide for 4 weeks (non-controlled patients)
Number of subjects: 823
Study: 14971627

Group type: EXPERIMENTAL
Intervention: Training for GPs in assessment and management of depression
Number of subjects: 189
Study: 10656838

Group type: EXPERIMENTAL
Intervention: High-intensity language messages
Number of subjects: 841

Group type: COMPARATOR
Intervention: Low-intensity language messages
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: High-intensity language with deductive argument style
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Low-intensity language with inductive argument style
Number of subjects: 841
Study: 9088813

Group type: EXPERIMENTAL
Intervention: Intraarticular morphine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraarticular morphine 1 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline 20 mL (Control)
Number of subjects: 0
Study: 8258574

Group type: EXPERIMENTAL
Intervention: Indirect photographic method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct method
Number of subjects: 0
Study: 3512926

Group type: EXPERIMENTAL
Intervention: Intervention group (received all interventions including mailed packets, appointment reminders, and follow-up)
Number of subjects: 859

Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 859
Study: 30790098

Group type: EXPERIMENTAL
Intervention: Family accommodation (FA)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Comorbid anxiety disorders
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Internalizing and externalizing problems
Number of subjects: 150
Study: 28389421

Group type: EXPERIMENTAL
Intervention: Web-based e-screening
Number of subjects: 636

Group type: COMPARATOR
Intervention: Paper-based screening
Number of subjects: 636
Study: 25170994

Group type: EXPERIMENTAL
Intervention: HERMITAGE intervention (n=350)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Attention control condition (n=350)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 700
Study: 22648289

Group type: EXPERIMENTAL
Intervention: rasburicase
Number of subjects: 26

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study: 21753777

Group type: EXPERIMENTAL
Intervention: Exercise program (twice a week for 6 months, emphasizing swimming)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 35
Study: 20110025

Group type: EXPERIMENTAL
Intervention: SAMe 1200 mg/d (400 mg TID)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Nabumetone 1000 mg/d (once daily in the evening)
Number of subjects: 134
Study: 17126782

Group type: EXPERIMENTAL
Intervention: Lidocaine 10 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 160
Study: 15067407

Group type: EXPERIMENTAL
Intervention: Goodwin‐Hohenfellner technique
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Abol‐Enein modification
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Le‐Duc procedure
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Mainz pouch II
Number of subjects: 83
Study: 11902591

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNβ‐1a)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9277010

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 939

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 939
Study: 8339409

Group type: EXPERIMENTAL
Intervention: Warfarin prophylaxis (adjusted to prolong INR to 1.5 on the day of surgery and 2.5 after surgery)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: NPA measurement
Number of subjects: 97

Group type: COMPARATOR
Intervention: Prothrombin time index and INR
Number of subjects: 97

Group type: COMPARATOR
Intervention: Transfusion on the day of surgery
Number of subjects: 97

Group type: COMPARATOR
Intervention: Prothrombin time index, INR, and NPA concentration
Number of subjects: 97
Study: 3711364

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30734696

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline mortality risk
Number of subjects: 0
Study: 30334917

Group type: EXPERIMENTAL
Intervention: Spreader graft technique
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Mattress suture technique
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (no graft and suture)
Number of subjects: 210
Study: 26679955

Group type: EXPERIMENTAL
Intervention: Aggression regulation intervention plus supportive contact
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supportive contact only
Number of subjects: 40
Study: 24996842

Group type: EXPERIMENTAL
Intervention: Synbiotic therapy for 6 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Synbiotic therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 22341825

Group type: EXPERIMENTAL
Intervention: Cash transfer programme (conditional and unconditional)
Number of subjects: 1289
Study: 20038863

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Diode grid laser
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard Early Treatment Diabetic Retinopathy Study focal laser treatment
Number of subjects: 86
Study: 18268090

Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Number of subjects: 80
Study: 16580904

Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg twice daily on the first day and 200 mg twice daily on the second day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous midazolam
Number of subjects: 10
Study: 12757533

Group type: EXPERIMENTAL
Intervention: Automated cell processor
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard centrifugation technique
Number of subjects: 40
Study: 10991661

Group type: EXPERIMENTAL
Intervention: Budipine
Number of subjects: 2532
Study: 9296215

Group type: EXPERIMENTAL
Intervention: Molgramostim 5 micrograms/kg every 12 hours for 14 days, given alongside chemotherapy regimens.
Number of subjects: 21
Study: 8466730

Group type: EXPERIMENTAL
Intervention: isradipine
Number of subjects: 268

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 268

Group type: COMPARATOR
Intervention: methyldopa
Number of subjects: 268

Group type: COMPARATOR
Intervention: normotensive subjects
Number of subjects: 268
Study: 3892383

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Naproxen 750 mg daily
Number of subjects: 20
Study: 30606383

Group type: EXPERIMENTAL
Intervention: CT angiography using low-voltage (80 kVp) and low-concentration contrast media (300 mgI/ml) with IMR algorithm
Number of subjects: 71

Group type: COMPARATOR
Intervention: CT angiography using regular voltage (100 kVp) and higher concentration contrast media (370 mgI/ml) with hybrid iterative reconstruction technique
Number of subjects: 71
Study: 26907736

Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and sofosbuvir (400 mg) once daily plus ribavirin (600‐1200 mg daily) for 12 weeks
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and sofosbuvir (400 mg) once daily plus ribavirin (600‐1200 mg daily) for 24 weeks
Number of subjects: 333
Study: 24310443

Group type: EXPERIMENTAL
Intervention: Orocutaneous stimulation during gavage feedings
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham condition (control)
Number of subjects: 22
Study: 22269678

Group type: EXPERIMENTAL
Intervention: Fresh corneal graft
Number of subjects: 37

Group type: COMPARATOR
Intervention: Frozen corneal graft
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study: 19787345

Group type: EXPERIMENTAL
Intervention: Haptic guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Error amplification
Number of subjects: 0
Study: 18366766

Group type: EXPERIMENTAL
Intervention: Open-label continuous combined hormone therapy
Number of subjects: 1823

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1823

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 1823

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1823
Study: 15604942

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with monitoring using (99m)Tc-Sestamibi scintimammography
Number of subjects: 26
Study: 15552853

Group type: EXPERIMENTAL
Intervention: Teeth in malocclusion
Number of subjects: 83

Group type: COMPARATOR
Intervention: Teeth in normal occlusion
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Pulp vitality threshold
Number of subjects: 83
Study: 10482155

Group type: EXPERIMENTAL
Intervention: Reduced Ejection Fraction (<55%)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Reduced Stress-Corrected MWS (<89.2%)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Normal Ejection Fraction (>55%)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Normal Stress-Corrected MWS (>89.2%)
Number of subjects: 212
Study: 8618181

Group type: EXPERIMENTAL
Intervention: ranitidine
Number of subjects: 29

Group type: COMPARATOR
Intervention: cisapride
Number of subjects: 29
Study: 1656149

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6633596

Group type: EXPERIMENTAL
Intervention: Presence of progesterone receptors
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Presence of estrogen receptors
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Combination of estrogen and progesterone receptors
Number of subjects: 189
Study: 31827353

Group type: EXPERIMENTAL
Intervention: On-ice agility training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Off-ice agility training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of training effects
Number of subjects: 14
Study: 29126981

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 1200 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 26857782

Group type: EXPERIMENTAL
Intervention: 7.5 mg ropivacaine plus 5 μg dexmedetomidine (RD)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 7.5 mg ropivacaine plus 15 μg fentanyl (RF)
Number of subjects: 108

Group type: COMPARATOR
Intervention: 7.5 mg ropivacaine (R)
Number of subjects: 108
Study: 25164793

Group type: EXPERIMENTAL
Intervention: Wheat bran extract (WBE)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oligofructose
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 22222291

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHG) in alcohol (more than 0.5%)
Number of subjects: 0
Study: 19153116

Group type: EXPERIMENTAL
Intervention: FOLFIRI-3 (irinotecan 100 mg/m(2) days 1 and 3 combined with LV 400 mg/m(2) day 1 and 46-h continuous 5-FU 2000 mg/m(2))
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: FOLFIRI-1 (irinotecan 180 mg/m(2) day 1 combined with LV 400 mg/m(2) day 1, 5-FU bolus 400 mg/m(2) and 46-h continuous 5-FU 2400 mg/m(2))
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Other irinotecan-based regimens
Number of subjects: 342
Study: 17472599

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 478

Group type: COMPARATOR
Intervention: Paroxetine 20 mg
Number of subjects: 478
Study: 15182413

Group type: EXPERIMENTAL
Intervention: 1 day antibiotic prophylaxis (ciprofloxacin or levofloxacin)
Number of subjects: 363

Group type: COMPARATOR
Intervention: 3 day antibiotic prophylaxis (ciprofloxacin or levofloxacin)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: 1 day antibiotic prophylaxis
Number of subjects: 363

Group type: COMPARATOR
Intervention: 3 day antibiotic prophylaxis
Number of subjects: 363
Study: 12201823

Group type: EXPERIMENTAL
Intervention: GH 1.5 IU/m2
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: GH 3.0 IU/m2
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: GH 6.0 IU/m2
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-GH treatment
Number of subjects: 17
Study: 9812183

Group type: EXPERIMENTAL
Intervention: High-dose standard heparin 300 U/kg as an intravenous bolus
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo bolus
Number of subjects: 48
Study: 8588268

Group type: EXPERIMENTAL
Intervention: Right adrenalectomy with liver mobilization
Number of subjects: 21

Group type: COMPARATOR
Intervention: Right adrenalectomy without mobilizing the liver
Number of subjects: 21
Study: 2693117

Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4‐MP) at 10 mg.kg‐1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4‐MP) at 20 mg.kg‐1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4‐MP) at 100 mg.kg‐1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4‐MP) overall
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 648211

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus cyclophosphamide
Number of subjects: 287

Group type: COMPARATOR
Intervention: Cyclophosphamide alone
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus CCNU
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus CCNU
Number of subjects: 287
Study: 31541626

Group type: EXPERIMENTAL
Intervention: AI-assisted sedated C-EGD
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Unsated U-TOE
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Unsated C-EGD
Number of subjects: 437

Group type: COMPARATOR
Intervention: AI subgroup (sedated C-EGD)
Number of subjects: 437

Group type: COMPARATOR
Intervention: AI subgroup (unsedated U-TOE)
Number of subjects: 437

Group type: COMPARATOR
Intervention: AI subgroup (unsedated C-EGD)
Number of subjects: 437
Study: 30632155

Group type: EXPERIMENTAL
Intervention: 4 CDC-based PA strategies
Number of subjects: 4894

Group type: COMPARATOR
Intervention: Routine PA programs
Number of subjects: 4894
Study: 28651249

Group type: EXPERIMENTAL
Intervention: TRO40303 (intravenous bolus)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 25604090

Group type: EXPERIMENTAL
Intervention: Social media intervention for low-income adolescent mothers; delivered via a web-based application over 6 weeks, includes daily behavioral challenges, text message reminders, discussion forums, and website information.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control group); participants continue to receive usual care during the intervention.
Number of subjects: 100
Study: 23882457

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21478219

Group type: EXPERIMENTAL
Intervention: CT score
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pulmonary function (expressed as Z-scores)
Number of subjects: 39
Study: 19543563

Group type: COMPARATOR
Intervention: Switching to another SSRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Switching to a dual reuptake inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Switching to another mechanism of action
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Augmentation strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive therapy as a switch or augmentation strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants in augmentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Remission rates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recurrence rates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients achieving remission
Number of subjects: 0
Study: 17465354

Group type: EXPERIMENTAL
Intervention: Ulna implants with surrounding bone blocks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional sinus augmentation with particulated autogenous bone grafts
Number of subjects: 20
Study: 15649285

Group type: EXPERIMENTAL
Intervention: ISO (100 mg) tablets
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo tablets (P group) containing vitamins C (25 mg) and E (5 mg)
Number of subjects: 81
Study: 11257292

Group type: EXPERIMENTAL
Intervention: Microtensile test method
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chevron-notched short-bar (CNSB) test method
Number of subjects: 40
Study: 9533351

Group type: EXPERIMENTAL
Intervention: Intensive medical treatment with oral agents and exogenous insulin injection
Number of subjects: 0
Study: 7546098

Group type: EXPERIMENTAL
Intervention: Test Group underpad
Number of subjects: 107

Group type: COMPARATOR
Intervention: Reference Group underpad
Number of subjects: 107
Study: 3391875

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Erythromycin base (EB) enterotablet A 500 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Erythromycin base (EB) enterotablet B 500 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Erythromycin base (EB) enterotablet A 500 mg (multiple dosing)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Erythromycin base (EB) enterotablet B 500 mg (multiple dosing)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cimetidine 400 + 800 mg
Number of subjects: 29
Study: 29363287

Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily (LOR BID)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily (LOR BID) + Phentermine 15 mg once daily (LOR BID + PHEN QD)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily (LOR BID) + Phentermine 15 mg twice daily (LOR BID + PHEN BID)
Number of subjects: 235
Study: 27353237

Group type: EXPERIMENTAL
Intervention: Temporary, transcutaneous, pharmaceutical SGB with lidocaine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36